{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patritumab+deruxtecan", "query": { "intervention": "Patritumab deruxtecan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patritumab+deruxtecan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T12:38:48.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05620914", "title": "A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases, Adult" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-07", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05620914" }, { "nct_id": "NCT04619004", "title": "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer Metastatic", "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor" ], "interventions": [ { "name": "Patritumab Deruxtecan (Fixed dose)", "type": "DRUG" }, { "name": "Patritumab Deruxtecan (Up-Titration)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2021-02-02", "completion_date": "2027-01-04", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 33, "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04619004" }, { "nct_id": "NCT04479436", "title": "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Patritumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2020-09-14", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 21, "location_summary": "Fayetteville, Arkansas • Duarte, California • Aurora, Colorado + 17 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04479436" }, { "nct_id": "NCT06596694", "title": "Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2024-11-03", "completion_date": "2028-12-07", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06596694" }, { "nct_id": "NCT05338970", "title": "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nonsquamous Non-small Cell Lung Cancer", "EGFR L858R", "EGFR Exon 19 Deletion" ], "interventions": [ { "name": "Patritumab Deruxtecan", "type": "DRUG" }, { "name": "Platinum-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 586, "start_date": "2022-07-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 23, "location_summary": "Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338970" }, { "nct_id": "NCT06686394", "title": "Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Biosimilar", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Tucatinib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2025-02-26", "completion_date": "2030-04-18", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 5, "location_summary": "Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06686394" }, { "nct_id": "NCT06941272", "title": "A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Patritumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 50, "start_date": "2025-05-26", "completion_date": "2030-12-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 17, "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06941272" }, { "nct_id": "NCT06797635", "title": "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Epirubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2025-03-20", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 8, "location_summary": "Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Billings", "state": "Montana" }, { "city": "Tigard", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06797635" }, { "nct_id": "NCT04699630", "title": "A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "U3-1402", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2021-05-03", "completion_date": "2025-04-09", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699630" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-18T12:38:48.773Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" } ] }